Pelthos' Zelsuvmi sales more than double in third quarter as Castle Creek deal approaches
Pelthos Therapeutics booked $15.2M in Zelsuvmi net revenue for the quarter, topped up its Horizon debt facility and says its Castle Creek merger should complete by the end of March 2027.
Pelthos Therapeutics said net revenue from its dermatology product Zelsuvmi reached $15.2M in the third quarter of 2026, up 114% on the comparable period. The figures were published on 12 November.
The company also said commercial-plan access for the product now spans 127 million covered lives. Pelthos presents this as part of the backdrop to the sales growth. Its update does not say which payers or plans were added, so the extent to which individual insurers drove the gain is not clear.
The other major item is the pending merger with Castle Creek Biosciences, whose lead programme is D-Fi, a genetically modified cell therapy for dystrophic epidermolysis bullosa. Pelthos expects the transaction to complete by the end of the first quarter of 2027. The material reviewed does not include deal terms or a valuation.
On funding, Pelthos has amended its loan agreement with Horizon Technology Finance so that it provides up to $50M. The company drew a further $10M under the revised terms on 30 October.
Why it matters
- Zelsuvmi's revenue more than doubling gives Pelthos a commercial track record as it prepares to take on a cell-therapy asset.
- The 127 million covered lives figure matters to market-access teams, though the absence of payer detail limits what can be inferred about the quality of that coverage.
- The Castle Creek merger would move Pelthos's portfolio beyond its current product into rare-disease cell therapy, with completion targeted for the end of Q1 2027.
- The larger Horizon facility, with $10M drawn on 30 October, shows debt is part of how Pelthos is financing its position ahead of the merger.
Company's press release (SEC filing): Pelthos Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
